The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
LAG-3
cancer
diagnosis
immune checkpoint
immunotherapy
oncology
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Dec 2020
23 Dec 2020
Historique:
received:
09
11
2020
revised:
17
12
2020
accepted:
18
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
10
3
2021
Statut:
epublish
Résumé
The blockade of immune checkpoints (ICPs), such as cytotoxic T lymphocyte associated protein-4 (CTLA-4) and programmed death-1 (PD-1) and its ligand (PD-L1), has propelled the field of immuno-oncology into its current era. Drugs targeting these ICPs have improved clinical outcome in a number of patients with solid and hematological cancers. Nonetheless, some patients have no benefit from these ICP-blocking therapies. This observation has instigated research into alternative pathways that are responsible for the escape of cancer cells from anti-cancer immune responses. From this research, a number of molecules have emerged as promising therapeutic targets, including lymphocyte activating gene-3 (LAG-3), a next-generation ICP. We will review the current knowledge on the biological activity of LAG-3 and linked herewith its expression on activated immune cells. Moreover, we will discuss the prognostic value of LAG-3 and how LAG-3 expression in tumors can be monitored, which is an aspect that is of utmost importance, as the blockade of LAG-3 is actively pursued in clinical trials.
Identifiants
pubmed: 33374804
pii: ijms22010075
doi: 10.3390/ijms22010075
pmc: PMC7795594
pii:
doi:
Substances chimiques
Antigens, CD
0
Biomarkers, Tumor
0
Immune Checkpoint Inhibitors
0
Lymphocyte Activation Gene 3 Protein
0
Lag3 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1501019N, I001618N, 1S24218N
Organisme : Kom op tegen Kanker
ID : Emmanuel Vanderscheuren
Organisme : Belgian Foundation against Cancer
ID : N/A
Organisme : Flemish cancer society
ID : N/A
Références
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Clin Cancer Res. 2020 Jul 1;26(13):3333-3344
pubmed: 32299814
Biomolecules. 2019 Sep 29;9(10):
pubmed: 31569553
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32540859
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9
pubmed: 9159144
Mol Cancer Ther. 2019 Nov;18(11):2051-2062
pubmed: 31395688
Sci Rep. 2016 Aug 01;6:30636
pubmed: 27477778
Nature. 2019 Jul;571(7764):270-274
pubmed: 31207604
Eur J Cancer. 2001 Sep;37(13):1709-18
pubmed: 11527700
Nature. 2019 Mar;567(7749):530-534
pubmed: 30814732
J Immunol. 1999 Mar 1;162(5):2748-53
pubmed: 10072520
Eur J Immunol. 2001 Oct;31(10):2885-91
pubmed: 11592063
Immunity. 2017 Dec 19;47(6):1114-1128.e6
pubmed: 29221730
FASEB J. 2012 Oct;26(10):3969-79
pubmed: 22730440
Biochim Biophys Acta. 1999 Apr 12;1431(1):37-46
pubmed: 10209277
Oncotarget. 2017 May 29;8(37):61425-61439
pubmed: 28977875
J Hematol Oncol. 2020 Apr 3;13(1):28
pubmed: 32245463
Invest New Drugs. 2013 Jun;31(3):707-13
pubmed: 22864469
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415
pubmed: 31152140
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13974-9
pubmed: 19666526
Eur J Immunol. 1995 Sep;25(9):2718-21
pubmed: 7589152
Oncotarget. 2019 Mar 12;10(21):2030-2040
pubmed: 31007846
J Immunol. 2014 Sep 15;193(6):3101-12
pubmed: 25108024
Cancer Immunol Immunother. 2015 Jul;64(7):853-60
pubmed: 25893809
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
FASEB J. 1996 May;10(7):769-76
pubmed: 8635694
Immunol Lett. 2013 Feb;150(1-2):116-22
pubmed: 23261718
Nat Rev Immunol. 2011 Nov 11;11(12):823-36
pubmed: 22076556
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
Blood. 2018 Apr 5;131(14):1617-1621
pubmed: 29439955
Br J Cancer. 2013 Nov 12;109(10):2629-35
pubmed: 24169351
J Immunol. 2009 Feb 15;182(4):1885-91
pubmed: 19201841
J Clin Med. 2020 Aug 03;9(8):
pubmed: 32756500
Blood Adv. 2020 Apr 14;4(7):1367-1377
pubmed: 32267932
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
Immunity. 2004 Oct;21(4):503-13
pubmed: 15485628
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Front Immunol. 2018 Aug 31;9:1977
pubmed: 30233579
Cancer Res. 2014 Jul 1;74(13):3418-28
pubmed: 24769443
Cancer Biomark. 2018;23(3):341-351
pubmed: 30223387
J Immunol. 2010 Jun 1;184(11):6545-51
pubmed: 20421648
J Biol Chem. 2004 Apr 30;279(18):18748-58
pubmed: 14711836
Immunity. 2015 Feb 17;42(2):265-278
pubmed: 25680272
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Theranostics. 2018 Jun 7;8(13):3559-3570
pubmed: 30026866
Int J Cancer. 2021 Feb 1;148(3):759-768
pubmed: 33105024
Haematologica. 2017 May;102(5):874-882
pubmed: 28154084
Vaccine. 2003 Feb 14;21(9-10):862-8
pubmed: 12547595
J Exp Med. 2011 Feb 14;208(2):395-407
pubmed: 21300912
Oncotarget. 2015 Sep 29;6(29):27359-77
pubmed: 26318293
J Clin Invest. 2007 Nov;117(11):3383-92
pubmed: 17932562
Nat Rev Immunol. 2015 Jan;15(1):45-56
pubmed: 25534622
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Clin Nucl Med. 1997 Sep;22(9):615-20
pubmed: 9298295
Nat Rev Immunol. 2016 Apr;16(4):220-33
pubmed: 27026074
Nat Immunol. 2018 Dec;19(12):1415-1426
pubmed: 30349037
Theranostics. 2014 Jan 29;4(4):386-98
pubmed: 24578722
FASEB J. 2002 Feb;16(2):240-2
pubmed: 11772942
J Transl Med. 2010 Jul 23;8:71
pubmed: 20653948
J Transl Med. 2020 Aug 6;18(1):306
pubmed: 32762721
Clin Cancer Res. 2016 Mar 15;22(6):1330-40
pubmed: 26500235
Cytokine. 2014 Jan;65(1):33-41
pubmed: 24139237
Vet Immunol Immunopathol. 2010 Jan 15;133(1):72-9
pubmed: 19631993
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Trends Immunol. 2003 Dec;24(12):619-22
pubmed: 14644131
EMBO J. 2007 Jan 24;26(2):494-504
pubmed: 17245433
Oncoimmunology. 2012 Nov 1;1(8):1239-1247
pubmed: 23243587
Nat Commun. 2015 Feb 19;6:6329
pubmed: 25695838
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Nature. 2019 Mar;567(7749):525-529
pubmed: 30814730
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234464
Front Oncol. 2019 Oct 15;9:1040
pubmed: 31681578
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32819974
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Nat Med. 2013 Jun;19(6):739-46
pubmed: 23624599
J Biol Chem. 2019 Apr 12;294(15):6017-6026
pubmed: 30760527
Ann Oncol. 2017 Dec 1;28(12):2977-2984
pubmed: 29045526
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
J Immunol. 2008 May 1;180(9):5916-26
pubmed: 18424711
Am J Cancer Res. 2015 Jun 15;5(7):2190-201
pubmed: 26328249
Eur J Immunol. 2002 Jun;32(6):1605-13
pubmed: 12115643
Immunity. 2018 Jul 17;49(1):120-133.e9
pubmed: 30005826
Cancers (Basel). 2019 Aug 20;11(8):
pubmed: 31434339
Mol Immunol. 2006 Feb;43(5):410-9
pubmed: 16337483
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Nat Rev Clin Oncol. 2017 Dec;14(12):712
pubmed: 28994421
J Neurochem. 2005 Nov;95(4):1201-14
pubmed: 16271053
Oncoimmunology. 2017 Dec 21;7(3):e1356144
pubmed: 29399387
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
J Cancer. 2019 Apr 5;10(7):1745-1754
pubmed: 31205530
Biochim Biophys Acta. 2016 Mar;1863(3):427-437
pubmed: 26264495
Int J Cancer. 2018 Dec 15;143(12):3201-3208
pubmed: 30248181
Ann Transl Med. 2019 Dec;7(23):776
pubmed: 32042792
J Cancer Res Clin Oncol. 2020 Sep;146(9):2319-2327
pubmed: 32592066
Mol Imaging Biol. 2018 Jun;20(3):361-367
pubmed: 29090412
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Imaging. 2020 Jan-Dec;19:1536012120960258
pubmed: 32957830
Immunol Lett. 1998 Apr;61(2-3):109-12
pubmed: 9657262
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
J Clin Invest. 2019 Jun 18;129(9):3770-3785
pubmed: 31211698
Cell Biol Int. 2007 Mar;31(3):257-62
pubmed: 17175182
Eur J Immunol. 2002 Aug;32(8):2255-63
pubmed: 12209638
J Invest Dermatol. 2014 Jul;134(7):1893-1902
pubmed: 24441096
Eur J Immunol. 2005 Jul;35(7):2081-8
pubmed: 15971272
Br J Cancer. 2020 May;122(10):1507-1517
pubmed: 32203221
J Immunol. 2013 May 1;190(9):4899-909
pubmed: 23536636
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
J Transl Med. 2014 Apr 12;12:97
pubmed: 24726012